Form 8-K · Current report
Merck & Co. 8-K, filed Aug 4, 2026
- Filed
- CIK
- 0000310158
- Accession no.
- 0001104659-26-090045
Summary
Merck & Co. reported second-quarter 2026 worldwide sales of $16.6 billion, up 5% from a year earlier, with a GAAP loss per share of $0.54 reflecting a $2.31-per-share charge for the acquisition of Terns Pharmaceuticals; the company narrowed and raised its full-year 2026 sales outlook to $66.3–$67.3 billion and its non-GAAP EPS guidance to $2.66–$2.76. During the quarter the FDA approved LIPFENDRA (enlicitide), described as the first once-daily oral PCSK9 inhibitor for lowering LDL-C in adults with hypercholesterolemia, and Merck reported positive Phase 3 results for a once-weekly oral HIV regimen of islatravir and lenacapavir developed with Gilead, and positive TroFuse-005 data for sacituzumab tirumotecan in advanced or recurrent endometrial cancer. Chairman and CEO Robert M. Davis said the company made substantial progress driven by new product launches and cited the LIPFENDRA approval as the latest milestone in its cardiovascular legacy.
Key points
- KEYTRUDA/KEYTRUDA QLEX sales were $8.4 billion, up 5%, including $463 million from KEYTRUDA QLEX; WINREVAIR sales rose 75% to $588 million.
- Animal Health sales were $1.8 billion, up 8%, and GARDASIL/GARDASIL 9 sales were $1.2 billion, up 4%.
- GAAP and non-GAAP results included a $2.31-per-share one-time charge for the Terns Pharmaceuticals acquisition, plus about $0.12 per share of financing costs and costs to advance MK-4208.
- Research and development expenses were $9.7 billion in the quarter, and gross margin was 73.5% versus 77.5% a year earlier.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. The following information, including the exhibits hereto, is being furnished pursuant to this Item 2.02. Incorporated by reference is a press release issued by Merck & Co., Inc. on August 4, 2026, regarding earnings for the second quarter of 2026, attached as Exhibit 99.1. Also incorporated by reference is certain supplemental information not included in the press release, attached as Exhibit 99.2. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.